The American Society of Hospital Pharmacists (ASHP) recently announced that a new AHFS Drug Information (AHFS DI) has been released.
“AHFS DI is the premier resource for the evidence-based information that health care practitioners need to make informed treatment and drug therapy recommendations,” Gerald McEvoy, editor-in-chief of AHFS DI and ASHP, said in a statement. “The 2017 edition is supported by more than 89,000 references and incorporates the expertise of hundreds of leading health professionals, providing the most thoroughly researched and comprehensive data on which to base therapeutic decisions.”
The AHFS DI includes a database of drug monographs; it features emerging information on cautions, drug interactions and therapeutic perspectives. These drug monographs are researched by pharmacists and professional editorial and analytical staff. Therapeutic recommendations come from esteemed organizations like the Centers for Disease Control and Prevention, the National Institutes of Health, the American Academy of Pediatrics, the American Heart Association, among others.
The 2017 edition has revised information about orphan drug products, therapeutic recommendations supported by evidence from primary research, extensive dosage and administration information, pharmacology and pharmacokinetics, prescription, OTC, ophthalmic, and dermatologic drugs, extensive off-label uses and related dosing options, vaccines and other immunizing agents.